Article Excerpt: The Center for Technology and Behavioral Health (CTBH) at the Geisel School of Medicine at Dartmouth has announced an innovative collaboration with Boehringer Ingelheim with the goal of advancing prescription digital therapeutics that specifically target serious mental illness. The collaboration will leverage each organization’s respective strengths in academic research and the healthcare industry to develop tools that can address the global mental health crisis.
“This collaboration embodies our commitment to bringing the best science to build the most effective, engaging tools,” said Lisa Marsch, PhD, founding director of CTBH and the Andrew G. Wallace Professor within the Departments of Psychiatry and Biomedical Data Science at Geisel School of Medicine. “We’re also deeply committed to scaling things that work and having an impact on people’s lives in the real world across the globe.”
Full Article: https://tinyurl.com/t97t3hd5
Article Source: Dartmouth Geisel School of Medicine News